|
|
Volumn 100, Issue 18, 2008, Pages 1280-1281
|
|
New response criteria proposed for immunotherapies
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
IPILIMUMAB;
MONOCLONAL ANTIBODY;
DISEASE COURSE;
HUMAN;
IMMUNOLOGY;
IMMUNOTHERAPY;
METHODOLOGY;
MORTALITY;
NEOPLASM;
NOTE;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
SURVIVAL;
SURVIVAL RATE;
TIME;
TREATMENT OUTCOME;
WORLD HEALTH ORGANIZATION;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
DISEASE PROGRESSION;
HUMANS;
IMMUNOTHERAPY;
NEOPLASMS;
SURVIVAL ANALYSIS;
SURVIVAL RATE;
TIME FACTORS;
TREATMENT OUTCOME;
WORLD HEALTH ORGANIZATION;
|
|
EID: 52649175424
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djn334 Document Type: Note |
|
Times cited : (16)
|
|
References (0)
|
